WallStreetZenWallStreetZen

NASDAQ: TLRY
Tilray Brands Inc Stock Forecast, Predictions & Price Target

Analyst price target for TLRY

Based on 1 analyst offering 12 month price targets for Tilray Brands Inc.
Min Forecast
$2.00+18.34%
Avg Forecast
$2.00+18.34%
Max Forecast
$2.00+18.34%

Should I buy or sell TLRY stock?

Based on 1 analyst offering ratings for Tilray Brands Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TLRY stock forecasts and price targets.

TLRY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-10

1 of 1

Forecast return on equity

Is TLRY forecast to generate an efficient return?
Company
2.94%
Industry
37.41%
Market
49.39%
TLRY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TLRY forecast to generate an efficient return on assets?
Company
2.4%
Industry
16.38%
TLRY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TLRY earnings per share forecast

What is TLRY's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.16
Avg 2 year Forecast
-$0.07
Avg 3 year Forecast
$0.12

TLRY revenue forecast

What is TLRY's revenue in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$901.6M+14.28%
Avg 2 year Forecast
$967.8M+22.68%
Avg 3 year Forecast
$1.1B+43.09%
TLRY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TLRY revenue growth forecast

How is TLRY forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
11.47%
Industry
6.49%
Market
9.63%
TLRY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TLRY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TLRY vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
TLRY$1.69$2.00+18.34%Hold
DVAX$11.02$22.00+99.64%Buy
INDV$10.42$23.00+120.73%Strong Buy
COLL$41.86$42.60+1.77%Buy
AVDL$13.09$24.00+83.35%Buy

Tilray Brands Stock Forecast FAQ

Is Tilray Brands Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: TLRY) stock is to Hold TLRY stock.

Out of 1 analyst, 0 (0%) are recommending TLRY as a Strong Buy, 0 (0%) are recommending TLRY as a Buy, 1 (100%) are recommending TLRY as a Hold, 0 (0%) are recommending TLRY as a Sell, and 0 (0%) are recommending TLRY as a Strong Sell.

If you're new to stock investing, here's how to buy Tilray Brands stock.

What is TLRY's earnings growth forecast for 2025-2027?

(NASDAQ: TLRY) Tilray Brands's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 20.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.6%.

Tilray Brands's earnings in 2024 is -$244,981,000.On average, 3 Wall Street analysts forecast TLRY's earnings for 2025 to be -$134,873,881, with the lowest TLRY earnings forecast at -$278,177,380, and the highest TLRY earnings forecast at -$42,148,088. On average, 2 Wall Street analysts forecast TLRY's earnings for 2026 to be -$54,792,514, with the lowest TLRY earnings forecast at -$75,866,558, and the highest TLRY earnings forecast at -$33,718,470.

In 2027, TLRY is forecast to generate $101,155,411 in earnings, with the lowest earnings forecast at $101,155,411 and the highest earnings forecast at $101,155,411.

What is TLRY's revenue growth forecast for 2025-2027?

(NASDAQ: TLRY) Tilray Brands's forecast annual revenue growth rate of 11.47% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.49%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.63%.

Tilray Brands's revenue in 2024 is $788,942,000.On average, 7 Wall Street analysts forecast TLRY's revenue for 2025 to be $760,032,022,308, with the lowest TLRY revenue forecast at $717,697,639,910, and the highest TLRY revenue forecast at $805,028,477,935. On average, 6 Wall Street analysts forecast TLRY's revenue for 2026 to be $815,852,949,857, with the lowest TLRY revenue forecast at $746,611,228,175, and the highest TLRY revenue forecast at $873,308,380,252.

In 2027, TLRY is forecast to generate $951,619,527,477 in revenue, with the lowest revenue forecast at $922,200,162,158 and the highest revenue forecast at $981,038,892,797.

What is TLRY's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: TLRY) forecast ROA is 2.4%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 16.38%.

What is TLRY's Price Target?

According to 1 Wall Street analyst that have issued a 1 year TLRY price target, the average TLRY price target is $2.00, with the highest TLRY stock price forecast at $2.00 and the lowest TLRY stock price forecast at $2.00.

The Wall Street analyst predicted that Tilray Brands's share price could reach $2.00 by Apr 10, 2025. The average Tilray Brands stock price prediction forecasts a potential upside of 18.34% from the current TLRY share price of $1.69.

What is TLRY's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TLRY) Tilray Brands's current Earnings Per Share (EPS) is -$0.33. On average, analysts forecast that TLRY's EPS will be -$0.16 for 2025, with the lowest EPS forecast at -$0.33, and the highest EPS forecast at -$0.05. On average, analysts forecast that TLRY's EPS will be -$0.07 for 2026, with the lowest EPS forecast at -$0.09, and the highest EPS forecast at -$0.04. In 2027, TLRY's EPS is forecast to hit $0.12 (min: $0.12, max: $0.12).

What is TLRY's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: TLRY) forecast ROE is 2.94%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.